World to Benefit from Rapid Implementation of Artificial Intelligence in Neurology Devices: Fact.MR Study

As per a new report by Fact.MR, a market research and competitive intelligence provider, the global neurology devices market is anticipated to reach a valuation of US$ 13 billion by 2027.

The prevalence of several neurological conditions as well as cerebrovascular disorders such as stroke, migraine, and headache is increasing across the world, which is driving up demand for neurology devices. Growing preference for minimally-invasive procedures and ongoing innovations in neurology equipment are also increasing market value.

With the support of non-invasive, image-guided neurology technologies, neurovascular issues such as tumors, cavernous malformations, and stroke are addressed. The market for neurology devices is expanding as a result of many key variables, including an increase in head traumas, high rates of stress in young people, an increase in the geriatric population, and a large patient base.

Rising patient awareness regarding the availability of treatment and reimbursement for neurovascular illnesses, particularly in emerging countries, are factors that will accelerate market expansion.

The use of artificial intelligence (AI) in neurology is anticipated to support market expansion. Computer-aided diagnosis (CAD) systems that employ AI and advanced signal processing methods can assist physicians in analyzing and understanding physiological signals and images more accurately.

Key Takeaways from Market Study

  • Worldwide demand for neurology devices is expected to rise at a CAGR of 6.2% through 2027.
  • The global neurology devices market is currently valued at US$ 9.6 billion.
  • The market in Canada is anticipated to expand at a CAGR of 5.5% over the forecast period (2022-2027).
  • Sales of interventional neurology devices are predicted to increase at a CAGR of 6.4% from 2022 to 2027.
  • The market in Germany is set to increase at a CAGR of 4% through 2027.

Market expansion is attributed to growing investments by key manufacturers of medical devices, increasing efforts by public & private institutions to improve and execute payment procedures for treating neurovascular disorders, and extensive research & development in neurotherapy,” says a Fact.MR analyst

Winning Strategy

Top companies are engaged in the introduction of magnetic stimulation technology as a result of innovations in neurostimulation and neuromodulation techniques. Key market players are collaborating with research organizations to increase their presence and contribute to the creation of modern as well as safe processes.

For instance,

  • In April 2022, an updated version of Abbott’s NeuroSphere myPath digital health app was released. Abbott neurostimulation devices are used by patients to treat their chronic pain, and the functionality of the app improved to help doctors better monitor their patients during this process.

These insights are based on a report on Neurology Diagnostics Devices Market by Fact.MR.

 

SourceFACT.MR

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."